Toronto Skyline

Featured image of Toronto by Wei Fang/Getty Images

Secondaries

Manulife secondaries co-head optimistic about GP-led deals with new fund

The fund is the first secondary vehicle raised by the asset manager to include third-party capital.

Manulife Investment Management, the asset management arm of Canadian insurance conglomerate Manulife, has unveiled its first fund dedicated to GP-led secondary deals.

The new pool of capital will ramp up Manulife’s capacity to invest in concentrated continuation funds, a market that has seen growing interest among secondary buyers in recent years.

This is the first fund raised by Manulife IM’s secondaries team to include third-party capital since the asset manager launched its secondaries platform in 2019.

The vehicle, known as Manulife Strategic Secondaries Fund, raised a significant amount of capital from external LPs, including pension plans, endowments, foundations, and private wealth managers in North America and Asia, according to Jeff Hammer, global co-head of the secondaries platform at Manulife IM.

The fund also includes capital from Manulife’s general accounts, bringing the total capital available for investing in GP-led secondaries to $610 million, Hammer said.

Hammer also added that he believes GP-led secondaries will generally generate higher returns than traditional LP-led secondary deals.

“We believe that, in time, what today is mostly a thesis will prove, through realizations and return of capital, the fundamental attractiveness of the GP-led value proposition,” he said. “ It is already happening.”

Hammer also said that he hopes that will occur this year while green shoots are emerging in the exit markets, including the recent uptick in IPO and M&A activity and lower financing costs from lenders who are compromising on pricing amid competition.

“The institutional pressures for liquidity have been building up, " Hammer added. “At a certain point, they need a release valve. The secondary market is a release valve. But you need more than that.”

Manulife Strategic Secondaries Fund will primarily target GP-led continuation funds containing no more than three assets, making bets typically between $25 million and $125 million.

Hammer didn’t disclose when the fundraising started but said the first close for the fund was in June 2022.

Several secondary firms have recently pitched new funds or raised fresh capital targeting GP-led continuation funds. The list includes LGT’s Crown Secondaries Special Opportunities III, Blackstone‘s $2.7 billion Strategic Partners GP Solutions, and Morgan Stanley’s Ashbridge Transformational Secondaries Fund II, which closed in early 2023 at $2.5 billion.

The rise of continuation funds

Continuation funds have been rising in prominence as GPs are plagued by the challenging exit environment, said Juliet Clemens, a fund strategies analyst at PitchBook.

A growing percentage of assets in private markets portfolios are approaching their time to exit. GPs don’t want to sell these assets at unfavorable prices, so they are extending the exit timeline by using continuation funds, Clemens explained.

In 2023, continuation funds accounted for 12% of sponsor-backed exit volume, compared with 7% seen in 2022, according to the Global Secondary Market Review released by Jefferies in January.

A handful of concentrated continuation funds have closed in the past few weeks.

OceanSound Partners, a technology-focused PE firm, closed a $1.15 billion single-asset continuation fund for portfolio company SMX Group. Apollo Global Management’s secondary platform, S3, was the lead investor in the syndicate.

In March, specialist healthcare manager Hildred Capital closed a more than $750 million continuation fund to extend its holding of two consumer healthcare businesses, Crown Laboratories and Hyland’s Naturals. Lexington Partners led the transaction.

Featured image of Toronto by Wei Fang/Getty Images

Learn about our editorial standards.